Impact of high-risk features on outcome of acute type B aortic dissection.
endovascular
high-risk features
type B aortic dissection
Journal
JTCVS open
ISSN: 2666-2736
Titre abrégé: JTCVS Open
Pays: Netherlands
ID NLM: 101768541
Informations de publication
Date de publication:
Mar 2023
Mar 2023
Historique:
received:
18
08
2022
revised:
21
11
2022
accepted:
06
01
2023
medline:
18
4
2023
entrez:
17
4
2023
pubmed:
18
4
2023
Statut:
epublish
Résumé
Acute type B aortic dissection (TBAD) is a severe condition associated with significant morbidity and mortality. The optimal classification and treatment strategy of TBAD remain controversial and inconsistent. This analysis includes patients treated for acute TBAD at the Helsinki University Hospital, Finland between 2007 and 2019. The endpoints were early and late mortality, intervention of the aorta, and a composite of death and aortic intervention in uncomplicated patients and high-risk patients. This study included 162 consecutive TBAD patients (27.8% females), 114 in the high-risk group and 48 in the uncomplicated group, with a mean age of 67.6 ± 13.9 years. Intramural hematoma was reported in 63 cases (38.9%). The mean follow-up was 5.1 ± 3.9 years. In-hospital/30-day mortality (n = 4; 3.5%) occurred solely in the high-risk group ( Recognition of risk factors underlying adverse events related to TBAD is essential because the disease progression impacts both early and late outcomes. Early aortic repair in high-risk TBAD may reduce long-term morbidity and mortality.
Sections du résumé
Background
UNASSIGNED
Acute type B aortic dissection (TBAD) is a severe condition associated with significant morbidity and mortality. The optimal classification and treatment strategy of TBAD remain controversial and inconsistent.
Methods
UNASSIGNED
This analysis includes patients treated for acute TBAD at the Helsinki University Hospital, Finland between 2007 and 2019. The endpoints were early and late mortality, intervention of the aorta, and a composite of death and aortic intervention in uncomplicated patients and high-risk patients.
Results
UNASSIGNED
This study included 162 consecutive TBAD patients (27.8% females), 114 in the high-risk group and 48 in the uncomplicated group, with a mean age of 67.6 ± 13.9 years. Intramural hematoma was reported in 63 cases (38.9%). The mean follow-up was 5.1 ± 3.9 years. In-hospital/30-day mortality (n = 4; 3.5%) occurred solely in the high-risk group (
Conclusions
UNASSIGNED
Recognition of risk factors underlying adverse events related to TBAD is essential because the disease progression impacts both early and late outcomes. Early aortic repair in high-risk TBAD may reduce long-term morbidity and mortality.
Identifiants
pubmed: 37063118
doi: 10.1016/j.xjon.2023.01.005
pii: S2666-2736(23)00012-8
pmc: PMC10091300
doi:
Types de publication
Journal Article
Langues
eng
Pagination
20-31Informations de copyright
© 2023 The Author(s).
Références
Cardiol Clin. 2017 Aug;35(3):387-410
pubmed: 28683909
J Vis Surg. 2018 Apr 23;4:75
pubmed: 29780721
J Vasc Surg. 2014 Jun;59(6):1544-54
pubmed: 24560244
Ann Cardiothorac Surg. 2014 Jul;3(4):403-5
pubmed: 25133104
N Engl J Med. 1999 May 20;340(20):1546-52
pubmed: 10332016
J Vasc Surg. 2018 Jan;67(1):78-84
pubmed: 28912006
J Card Surg. 2022 Apr;37(4):993-1001
pubmed: 34967980
Ann Cardiothorac Surg. 2021 Nov;10(6):784-786
pubmed: 34926181
Eur Heart J. 2014 Nov 1;35(41):2873-926
pubmed: 25173340
Ann Thorac Surg. 2022 Apr;113(4):1073-1092
pubmed: 35090687
J Vasc Surg. 2020 Mar;71(3):723-747
pubmed: 32001058
Eur J Vasc Endovasc Surg. 2014 Sep;48(3):285-91
pubmed: 24962744
J Am Coll Cardiol. 2019 Sep 17;74(11):1494-1504
pubmed: 31514953
Circulation. 2018 Apr 24;137(17):1846-1860
pubmed: 29685932
Eur J Vasc Endovasc Surg. 2021 May;61(5):788-797
pubmed: 33846073
Circulation. 2009 Dec 22;120(25):2519-28
pubmed: 19996018
N Engl J Med. 1994 Dec 29;331(26):1729-34
pubmed: 7984192
Eur J Vasc Endovasc Surg. 2014 Oct;48(4):363-71
pubmed: 24952999
Circ Cardiovasc Interv. 2013 Aug;6(4):407-16
pubmed: 23922146
J Card Surg. 2021 Oct;36(10):3820-3830
pubmed: 34310731